Esperion Therapeutics, Inc.
ESPR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $525,107 | $193,770 | $282,424 | $430,247 |
| - Cash | $92,447 | $86,061 | $114,633 | $144,761 |
| + Debt | $151,653 | $598,178 | $297,784 | $297,602 |
| Enterprise Value | $584,313 | $705,887 | $465,575 | $583,088 |
| Revenue | $87,309 | $82,385 | $64,995 | $69,113 |
| % Growth | 6% | 26.8% | -6% | – |
| Gross Profit | $31,889 | $53,842 | $33,457 | $43,482 |
| % Margin | 36.5% | 65.4% | 51.5% | 62.9% |
| EBITDA | -$9,256 | $7,788 | -$20,998 | -$4,869 |
| % Margin | -10.6% | 9.5% | -32.3% | -7% |
| Net Income | -$31,333 | -$12,725 | -$40,455 | -$21,318 |
| % Margin | -35.9% | -15.4% | -62.2% | -30.8% |
| EPS Diluted | -0.2 | -0.024 | -0.21 | -0.11 |
| % Growth | -726.4% | 88.5% | -90.9% | – |
| Operating Cash Flow | -$4,286 | -$31,422 | -$22,628 | -$34,952 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$4,286 | -$31,422 | -$22,628 | -$34,952 |